Duvernoy Claire S, Mosca Lori
Preventive Cardiology, New York Presbyterian Hospital, 622 West 168th Street, PH 10-203B, New York, NY 10032, USA.
Curr Atheroscler Rep. 2002 Mar;4(2):156-60. doi: 10.1007/s11883-002-0040-4.
Recent randomized trials of hormone replacement therapy (HRT) in postmenopausal women are not consistent with the decrease in cardiovascular risk seen in observational studies of hormone therapy users compared with nonusers. Emerging evidence indicates that HRT use in some women with established coronary heart disease may be associated with prothrombotic effects or proinflammatory effects leading to adverse events. In healthy women, the decision to use HRT should be based primarily on noncardiac factors until more data becomes available that is relevant to this population. Several alternatives to HRT, including phytoestrogens and selective estrogen receptor modulators, have favorable effects on cardiovascular risk factors, but their impact on clinical outcomes remains to be determined.
